Stephen T Wrobleski

4PUBLICATIONS
20CO-AUTHORS
Biomolecular modelling and designAutoimmunityBiologically active moleculesCheminformatics and quantitative structure-activity relationships
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Sep 25, 2025
Discovery of Potent and Selective Reversible Ubiquitin-Like Modifier Activating Enzyme 5 Inhibitors Targeting the UFMylation Pathway.

James J Mignone, Elizabeth A Jurica, Deepa Rajasekaran

|Jul 26, 2019
Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain.

James R Burke, Lihong Cheng, Kathleen M Gillooly

|Jul 19, 2019
Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165.

Stephen T Wrobleski, Ryan Moslin, Shuqun Lin

|Jul 18, 2019
Identification of N-Methyl Nicotinamide and N-Methyl Pyridazine-3-Carboxamide Pseudokinase Domain Ligands as Highly Selective Allosteric Inhibitors of Tyrosine Kinase 2 (TYK2).

Ryan Moslin, Yanlei Zhang, Stephen T Wrobleski

Pageof 1

Frequent Collaborators

3 joint publications

Ryan Moslin

2 joint publications

Steven Spergel

2 joint publications

Percy H Carter

1 joint publications

James Kempson